- Stocks
- Pharma & Healthcare
- Nidan Lab
Nidan Lab share price
NSE: NIDANPharma & Healthcare
Nidan Lab at a glance
Nidan Lab (NSE: NIDAN) closed at ₹12.65 on 21 Oct 2026. With a market capitalisation of ₹18 Cr, it ranks 3630th by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector.
Its return on equity was 2.9% in FY25. Over the past year the share price has fallen 31.3%. Its 52-week range is ₹11.50 (25 Jun 2026) to ₹24.90 (1 Dec 2025); the last close is 49.2% below the high. Promoters held 57.04% of the company as of 30 Jun 2026.
Key numbers
- Market cap
- ₹18 CrRank 3630 on NSE
- Price to book
- 0.34×FY25
- ROE
- 2.9%FY25
- ROCE
- 6.7%FY25
- Debt to equity
- 0.16FY25
- Net profit margin
- 8.1%FY25
- Book value / share
- ₹49.05FY25
- 52-week high
- ₹24.901 Dec 2025
- 52-week low
- ₹11.5025 Jun 2026
- 1-year return
- −31.3%
- RSI (14-day)
- 44.7
Returns to 22 Oct 2026
| Period | 1 day | 1 week | 1 month | 3 months | 1 year |
|---|---|---|---|---|---|
| Price change | 0.00% | −2.7% | −6.3% | −7.0% | −31.3% |
Nidan Lab financials
| Item | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|
| Revenue | ₹22 Cr | ₹20 Cr | ₹30 Cr | ₹24 Cr | ₹24 Cr | ₹25 Cr |
| Operating profit | ₹1 Cr | ₹3 Cr | ₹5 Cr | ₹5 Cr | ₹4 Cr | ₹3 Cr |
| Net profit | ₹1 Cr | ₹2 Cr | ₹3 Cr | ₹4 Cr | −₹3 Cr | ₹2 Cr |
| EPS (₹) | ₹0.72 | ₹2.33 | ₹2.32 | ₹2.55 | −₹2.33 | ₹1.42 |
| Cash from operations | ₹5 Cr | ₹4 Cr | ₹8 Cr | ₹14 Cr | −₹15 Cr | ₹2 Cr |
| Total debt | ₹34 Cr | ₹14 Cr | ₹9 Cr | ₹5 Cr | ₹4 Cr | ₹4 Cr |
| Shareholders' equity | ₹11 Cr | ₹13 Cr | ₹66 Cr | ₹69 Cr | ₹66 Cr | ₹68 Cr |
Nidan Lab shareholding pattern
| Holder | 30 Sep 2024 | 31 Mar 2025 | 30 Sep 2025 | 31 Dec 2025 | 31 Mar 2026 | 30 Jun 2026 |
|---|---|---|---|---|---|---|
| Promoters | 57.04% | 57.04% | 57.04% | 57.04% | 57.04% | 57.04% |
| Non-institutions | 42.96% | 42.96% | 42.96% | 42.96% | 42.96% | 42.96% |
Nidan Lab vs peers
The listed Pharma & Healthcare companies nearest to Nidan Lab by market capitalisation.
Ask anything about Nidan Lab
Pivot answers on the live chart with evidence you can check, and tests strategies against NIDAN's own history. Try: “Why has NIDAN moved over the last three months?” · “Backtest a 50-day moving-average crossover on NIDAN over five years” · “Compare NIDAN with ADESHWAR on margins and valuation”
Frequently asked questions about Nidan Lab
What is the share price of Nidan Lab today?
Nidan Lab (NSE: NIDAN) last closed at ₹12.65 on 21 Oct 2026. Its 52-week high is ₹24.90 and its 52-week low is ₹11.50.
What is the market cap of Nidan Lab?
Nidan Lab's market capitalisation is ₹18 Cr (₹18 Cr) at the 22 Oct 2026 close, ranking 3630th among the NSE companies Pivot tracks.
What is the ROE and ROCE of Nidan Lab?
Return on equity was 2.9% in FY25 and return on capital employed was 6.7% in FY25 (standalone figures).
Is Nidan Lab a debt-free company?
No. Nidan Lab's debt-to-equity ratio was 0.16 in FY25, with total debt of ₹4 Cr.
How has Nidan Lab stock performed over the last year?
Nidan Lab's share price has fallen 31.3% over the past year, −7.0% over three months and −6.3% over one month, to the 22 Oct 2026 close.
What is the shareholding pattern of Nidan Lab?
As of 30 Jun 2026: promoters 57.04%, non-institutions 42.96%.
Who are Nidan Lab's competitors?
The listed Pharma & Healthcare companies closest to Nidan Lab by market cap are Adeshwar Medite, Maitri, Desh Rakshak, Vanta Bioscienc, Venmax Drugs and Zenith Health.
Is Nidan Lab a good stock to buy?
Pivot does not give buy or sell recommendations. This page sets out Nidan Lab's price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on NIDAN against its own history before risking money. This is analysis, not financial advice.
Sources and method
Prices: NSE daily closes to 21 Oct 2026 (returns and ratios at the 22 Oct 2026 close). Fundamentals: company filings via Moneycontrol, consolidated where available. Shareholding: exchange shareholding-pattern filings. The 52-week range uses intraday highs and lows; the chart marks closing prices. P/E is the last close over trailing twelve-month EPS. Market-cap rank is among the 4,183 NSE companies Pivot tracks; SEBI's bands call the top 100 large-cap and the next 150 mid-cap. Figures marked “—” are not available rather than zero. This is analysis, not financial advice.
More: all Pharma & Healthcare stocks · companies starting with N · all NSE stocks · this page as text